Boston Scientific (NYSE:BSX) Upgraded at Barclays

Barclays upgraded shares of Boston Scientific (NYSE:BSX) to a hold rating in a research note released on Wednesday morning,Zacks reports.

Several other analysts have also weighed in on BSX. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. BTIG Research reduced their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. Needham & Company LLC decreased their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Mizuho lowered their price objective on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Oppenheimer dropped their price objective on shares of Boston Scientific from $85.00 to $65.00 and set an “outperform” rating on the stock in a research note on Monday, September 21st. Twenty-two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.31.

Boston Scientific Stock Performance

Shares of BSX stock opened at $42.71 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company’s fifty day moving average price is $46.56 and its two-hundred day moving average price is $50.65. The firm has a market capitalization of $61.90 billion, a P/E ratio of 17.29, a P/E/G ratio of 1.01 and a beta of 0.58. Boston Scientific has a 12 month low of $41.38 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the firm earned $0.75 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts anticipate that Boston Scientific will post 3.25 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, Director Edward Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction dated Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GK Wealth Management LLC acquired a new position in Boston Scientific during the 3rd quarter valued at about $41,000. Riversedge Advisors LLC boosted its holdings in shares of Boston Scientific by 83.2% in the third quarter. Riversedge Advisors LLC now owns 13,733 shares of the medical equipment provider’s stock valued at $599,000 after acquiring an additional 6,237 shares in the last quarter. Wedmont Private Capital increased its stake in shares of Boston Scientific by 6.3% during the third quarter. Wedmont Private Capital now owns 27,800 shares of the medical equipment provider’s stock valued at $1,213,000 after acquiring an additional 1,652 shares during the period. LifeGoal Investments LLC bought a new stake in Boston Scientific during the third quarter worth approximately $428,000. Finally, Mn Services Vermogensbeheer B.V. raised its holdings in Boston Scientific by 8.1% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 467,972 shares of the medical equipment provider’s stock worth $20,427,000 after purchasing an additional 34,959 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific sued Johnson & Johnson over alleged patent infringement involving a tool used in heart procedures. Although the litigation creates uncertainty, a successful outcome could help protect Boston Scientific’s intellectual property and competitive position. Boston Scientific sues J&J for patent infringement over heart procedure tool
• Neutral Sentiment: The company appointed Joseph Fitzgerald as chief operating officer and is reorganizing into three operating segments. The changes could improve accountability and execution, but investors may initially view the restructuring as an indication that management is seeking to streamline operations. Boston Scientific Names Joseph Fitzgerald as COO Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an Equal Weight rating, also described in related coverage as a Hold. The stance suggests the firm sees limited near-term outperformance potential rather than a strong bullish or bearish catalyst. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low near $41.50 amid elevated trading volume. The stock remains substantially below its 50-day average of $46.64 and 200-day average of $50.71, signaling weak momentum and continued investor caution. Boston Scientific Reaches New 1-Year Low

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.